NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients
NCT05743608 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1336
Last updated 2025-09-09
Summary
The goal of this observational study is to measure improvement in health related quality of life in moderate to severe COPD patients treated with Trimbow inhalation powder. The main question\[s\] it aims to answer are:
* Treatment's effect on quality of life
* Treatment's effect on lung function Participants will be assessed according to routine clinica practice, without any additional intervention.
Conditions
Sponsors & Collaborators
-
Chiesi Slovenija, d.o.o.
collaborator INDUSTRY -
Chiesi Bulgaria
collaborator INDUSTRY -
CHIESI CZ s.r.o.
collaborator UNKNOWN -
Chiesi Hungary Ltd.
lead INDUSTRY
Eligibility
- Min Age
- 35 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-29
- Primary Completion
- 2024-10-31
- Completion
- 2025-05-05
Countries
- Hungary
Study Locations
More Related Trials
-
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01372410 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00837629 ·Status: COMPLETED
-
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
NCT01023516 ·Status: COMPLETED ·Phase: PHASE2
-
A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD
NCT01636713 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days
NCT00732472 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD
NCT01393145 ·Status: WITHDRAWN ·Phase: PHASE3
-
2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients
NCT02579850 ·Status: COMPLETED ·Phase: PHASE3
-
PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)
NCT05652439 ·Status: RECRUITING
-
Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.
NCT01329276 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT01966549 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD
NCT04675463 ·Status: UNKNOWN ·Phase: NA
-
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers
NCT02743013 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
NCT04091360 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
NCT00783406 ·Status: COMPLETED ·Phase: PHASE2
-
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
NCT01313650 ·Status: COMPLETED ·Phase: PHASE3
-
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01316887 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®
NCT01048333 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01415518 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of CM326 in Subjects With Moderate to Severe Asthma
NCT05774340 ·Status: UNKNOWN ·Phase: PHASE2
-
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT02294734 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))
NCT01342913 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.
NCT01494610 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.
NCT06590740 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®
NCT00542880 ·Status: COMPLETED ·Phase: PHASE4
-
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00758459 ·Status: COMPLETED ·Phase: PHASE2